Antibody-Drug Conjugate: Transforming Cancer Treatment Options

Alpha Lifetech Incorporation is proud to present our latest innovation in cancer treatment, the Antibody-Drug Conjugate. This groundbreaking product combines the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs, allowing for targeted delivery of the drug to cancer cells while minimizing damage to healthy tissues. By attaching the drug directly to the antibody, the Antibody-Drug Conjugate ensures that the drug is only released when it reaches the cancer cells, maximizing its effectiveness and reducing the risk of adverse side effects, Our Antibody-Drug Conjugate has shown great promise in preclinical and clinical studies, with significant improvements in tumor response rates and progression-free survival compared to standard chemotherapy. This means that patients can experience better outcomes and a higher quality of life during their cancer treatment

Hot Selling Product

ALP64522-Recombinant Human BTLA/CD272 Protein, mFc Tag

ALP64529-Recombinant Human CD279/PD-1 Protein, His Tag, Avi Tag

ALP64550-Recombinant Human ILT3/CD85k/LILRB4 Protein, His Tag

ALP64557-Recombinant Human CD40L/TNFRSF5 Protein, mFc Tag

ADT1566-RSV-neutralizing Human Antibody (Am14) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

Champions of Antibody-Drug Conjugate Ahead of the Curve Your Trusted OEM Partner

At Alpha Lifetech Inc., we pride ourselves on being at the forefront of the rapidly evolving field of Antibody-Drug Conjugates (ADCs). Established by a team of seasoned scientists with rich expertise in membrane protein production, Nanobody discovery, and monoclonal antibody development, we have positioned ourselves as a trusted OEM partner for your research and development needs. With nearly 10,000 high-quality reagents in our catalog, including spot membrane protein reagents, cytokines, and drug target antibodies, we empower global procurement partners to advance their projects with confidence and precision. Our commitment to innovation and quality ensures that you gain access to state-of-the-art products that meet the highest scientific standards. We understand the complexities of ADC development and aim to provide comprehensive solutions tailored to your specific demands. By partnering with Alpha Lifetech, you not only benefit from our extensive product range but also tap into our team's profound industry insights and scientific support, enhancing your R&D capabilities. As we look ahead, we invite you to join us in forging new paths in therapeutic development. Together, we can transform challenges into breakthroughs, bringing impactful solutions to the forefront of healthcare. Trust Alpha Lifetech Inc. as your OEM partner, and let us help you stay ahead of the curve in this competitive landscape.

Champions of Antibody-Drug Conjugate Ahead of the Curve Your Trusted OEM Partner

Product	Innovative Features	Target Indication	Development Stage	Year of Launch
ADC-123	Enhanced specificity, Reduced off-target effects	Breast Cancer	Phase III	2024
ADC-456	Dual-action mechanism, Improved solubility	Non-Small Cell Lung Cancer	Phase II	2025
ADC-789	Targeted delivery system, High payload capacity	Ovarian Cancer	Preclinical	2026
ADC-101	Synergistic effects with immunotherapy	Hematologic Malignancies	Phase I	2023

Market Growth Trends of Antibody-Drug Conjugates (ADCs) by Year

The market for Antibody-Drug Conjugates (ADCs) has witnessed a remarkable growth trajectory over the past few years. As illustrated in the bar chart, the market value has increased from $5 billion in 2019 to an anticipated $20 billion by 2025. This significant growth can be attributed to advancements in biotechnology and an increasing number of ADCs entering the pipeline for various cancers and other diseases. The year-on-year increase reflects not only the rising acceptance of ADCs in clinical settings but also the growing investment in research and development to enhance the efficacy and safety profiles of these targeted therapies. Manufacturers and stakeholders in the healthcare industry are increasingly looking towards ADCs as a strategic focus area, driven by the demand for innovative treatment options and the need to improve patient outcomes. As such, the ADC market is expected to continue expanding, presenting numerous opportunities for collaboration and partnership for OEMs and other industry players.